Next Article in Journal
Development of Inhalable ATRA-Loaded PLGA Nanoparticles as Host-Directed Immunotherapy against Tuberculosis
Next Article in Special Issue
Implementation of Model-Based Dose Adjustment of Tobramycin in Adult Patients with Cystic Fibrosis
Previous Article in Journal
Nanoassemblies from Amphiphilic Sb Complexes Target Infection Sites in Models of Visceral and Cutaneous Leishmaniases
Previous Article in Special Issue
Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
 
 
Article

Article Versions Notes

Pharmaceutics 2022, 14(8), 1744; https://doi.org/10.3390/pharmaceutics14081744
Action Date Notes Link
article xml file uploaded 21 August 2022 15:55 CEST Original file -
article xml uploaded. 21 August 2022 15:55 CEST Update https://www.mdpi.com/1999-4923/14/8/1744/xml
article pdf uploaded. 21 August 2022 15:55 CEST Version of Record https://www.mdpi.com/1999-4923/14/8/1744/pdf
article html file updated 21 August 2022 15:57 CEST Original file -
article html file updated 24 August 2022 21:16 CEST Update https://www.mdpi.com/1999-4923/14/8/1744/html
Back to TopTop